Catalent Inc (NASDAQ:CTLT)’s share price traded down 3% on Friday . The stock traded as low as $24.53 and last traded at $24.57, with a volume of 817,583 shares trading hands. The stock had previously closed at $25.34.

Several equities analysts recently weighed in on the stock. Jefferies Group reaffirmed a “hold” rating on shares of Catalent in a research report on Thursday, August 4th. Zacks Investment Research raised shares of Catalent from a “strong sell” rating to a “hold” rating in a research report on Tuesday, July 5th. Wells Fargo & Co. raised shares of Catalent from a “market perform” rating to an “outperform” rating in a research report on Tuesday, June 21st. Finally, Bank of America Corp. raised shares of Catalent from a “neutral” rating to a “buy” rating and set a $28.00 target price on the stock in a research report on Monday, June 20th. They noted that the move was a valuation call.

The stock has a market cap of $3.07 billion and a PE ratio of 15.30. The company has a 50-day moving average of $24.15 and a 200-day moving average of $25.31.

In related news, major shareholder Blackstone Management Associat sold 8,785,539 shares of the business’s stock in a transaction dated Thursday, June 9th. The shares were sold at an average price of $24.51, for a total transaction of $215,333,560.89. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Matthew M. Walsh sold 21,197 shares of the business’s stock in a transaction dated Friday, May 27th. The shares were sold at an average price of $28.85, for a total transaction of $611,533.45. Following the transaction, the insider now owns 105,688 shares in the company, valued at approximately $3,049,098.80. The disclosure for this sale can be found here.

Catalent, Inc is a provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. The Company’s segments include Oral Technologies, Medication Delivery Solutions, and Development and Clinical Services. The Oral Technologies segment provides advanced oral delivery technologies, including formulation, development and manufacturing of oral dose forms for prescription and consumer health products across all phases of a molecule’s lifecycle.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.